LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

LLY

988.33

+0.72%↑

JNJ

240.32

+0.33%↑

ABBV

229.95

-0.9%↓

NVS

159.76

-0.49%↓

AZN

194.37

-1.51%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

27%

73%

69 / 351 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. märts 2026, 19:32 UTC

Omandamised, ülevõtmised, äriostud

Diana Shipping Increases Offer to Acquire Genco -- Update

6. märts 2026, 17:44 UTC

Omandamised, ülevõtmised, äriostud

Lonza to Offload Majority Stake in Capsule Business to Lone Star in $2.2 Billion Deal

6. märts 2026, 22:26 UTC

Uudisväärsed sündmused

Why $100 Oil Is Now in Sight. Who Wins, Who Loses. -- Barrons.com

6. märts 2026, 22:07 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Boeing Says Spirit Acquisition Will Help Improve Safety -- Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Global Equities Roundup: Market Talk

6. märts 2026, 22:03 UTC

Market Talk

Boeing CEO's Pay Nears $24 Million During Recovery Phase -- Market Talk

6. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Financial Services Roundup: Market Talk

6. märts 2026, 21:37 UTC

Tulu

Salesforce Stock Might Not Be an AI Loser After All -- Barrons.com

6. märts 2026, 21:25 UTC

Uudisväärsed sündmused

How The Iran War Impacts Ukraine. -- Barrons.com

6. märts 2026, 21:17 UTC

Tulu

Burlington Stores' Strong Year Should Lift the Stock. What Comes Next. -- Barrons.com

6. märts 2026, 20:50 UTC

Tulu

Marvell Stock Pops 20%. Semiconductor Earnings Show AI Demand Is Strong. -- Barrons.com

6. märts 2026, 20:46 UTC

Tulu

Nike Reports $300 Million Pretax Charge Related to Job Cuts -- Barrons.com

6. märts 2026, 20:31 UTC

Uudisväärsed sündmused

Oil Prices Soar Past $90. Trump Demands 'Unconditional Surrender' From Iran -- and Kuwait Cut Production. -- Barrons.com

6. märts 2026, 20:18 UTC

Market Talk

Oil Makes Record Weekly Gains As Strait of Hormuz Stays Shut -- Market Talk

6. märts 2026, 20:12 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Futures Gain on Global Energy Turmoil -- Market Talk

6. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

$150 Oil Seen As Realistic If Hormuz Closure Lasts -- Market Talk

6. märts 2026, 18:54 UTC

Market Talk

Fed's Hammack: Dollar Hasn't Lost Prime Status -- Market Talk

6. märts 2026, 18:44 UTC

Market Talk

Uudisväärsed sündmused

U.S. Oil Rig Count Increases By 4 to 411 -- Market Talk

6. märts 2026, 18:08 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 18:04 UTC

Tulu

Samsara Stock Jumps 16% After Earnings. Why the CEO Isn't Worried About AI. -- Barrons.com

6. märts 2026, 17:49 UTC

Market Talk

AI-Driven Picks-And-Shovels Bet Comes With Risks -- Market Talk

6. märts 2026, 17:46 UTC

Uudisväärsed sündmused

Kuwait Cuts Oil Production as Fallout From Iran Conflict Intensifies -- Update

6. märts 2026, 17:40 UTC

Market Talk

Tulu

Marvell's Long-Term Outlook Well-Received By Investors -- Market Talk

6. märts 2026, 17:40 UTC

Tulu

Marvell Stock Surges on Earnings. It's Not Just a Custom AI Chip Story. -- Barrons.com

6. märts 2026, 17:32 UTC

Market Talk

Uudisväärsed sündmused

No Quick Solution for Hormuz Shipping as U.S. Oil Tops $90 -- Market Talk

6. märts 2026, 17:28 UTC

Market Talk

Uudisväärsed sündmused

Aluminum Rising as Strait of Hormuz Stays Locked -- Market Talk

6. märts 2026, 17:20 UTC

Market Talk

Tulu

Auto & Transport Roundup: Market Talk

6. märts 2026, 17:20 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

6. märts 2026, 17:20 UTC

Omandamised, ülevõtmised, äriostud

BlackRock Sticks to Redemption Minimum on Credit Fund, Sends Shares Lower -- WSJ

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

69 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.